Norges Bank Stoke Therapeutics, Inc. Transaction History

Norges Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$3.78 - $11.99 $734,877 - $2.33 Million	-194,412 Closed	0 $0
Q2 2023 Aug 14, 2024	BUY	$7.93 - $13.82 $195,871 - $341,354	24,700 New	24,700 $262,000
Q2 2023 Aug 14, 2023	SELL	$7.93 - $13.82 $1.54 Million - $2.69 Million	-194,412 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $2.79 Million - $6.19 Million	394,312 New	394,312 $3.64 Million
Q3 2022 Nov 13, 2023	BUY	$12.56 - $22.53 $2.44 Million - $4.38 Million	194,412 New	194,412 $2.5 Million
Q2 2022 Aug 14, 2023	BUY	$10.36 - $23.93 $2.01 Million - $4.65 Million	194,412 New	194,412 $2.57 Million
Q1 2022 May 12, 2023	SELL	$17.19 - $26.1 $4.28 Million - $6.49 Million	-248,712 Reduced 63.07%	145,600 $3.06 Million
Q3 2021 Nov 14, 2022	BUY	$23.65 - $34.44 $1.07 Million - $1.56 Million	45,200 New	45,200 $1.15 Million
Q4 2019 Feb 12, 2020	SELL	$20.01 - $30.79 $500,250 - $769,750	-25,000 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$20.53 - $37.72 $513,250 - $943,000	25,000 New	25,000 $537,000
Q3 2019 Nov 08, 2019	SELL	$20.53 - $37.72 $513,250 - $943,000	-25,000 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$25.53 - $29.17 $638,250 - $729,250	25,000 New	25,000 $729,000

117

55.6M

14K

8.8K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $482M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.